Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Damora Therapeutics, Inc.NASDAQ: DMRA
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 3384.8% from a year ago
Total assets stood at $535.44M at the end of Q1 FY2026, up 3384.8% from a year earlier and up 105.5% from the prior quarter. Over 3 fiscal years it compounded at +52.7% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +3384.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 260.53M USD
- Year-over-year change
- +1420.7%
- 4-year CAGR
- +20.8%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 260.53M | +1420.7% |
| FY2024 | 2024-12-31 | 17.13M | -55.2% |
| FY2023 | 2023-12-31 | 38.23M | -47.8% |
| FY2022 | 2022-12-31 | 73.19M | -40.1% |
| FY2021 | 2021-12-31 | 122.22M | — |
Total Assets vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's Mar 2026 total assets of $535.44M is the 5th highest of the 9 companies compared; the peer median is $616.8M.
- Its year-over-year change of +3384.8% is the highest of 8, against a peer median of +28.6%.
- Over three fiscal years its annual growth of +52.7% compares with a peer median of +6.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Jun 2026 | $12.52B | +93.7% | -24.7% | |
| Jun 2026 | $7.87B | +35.2% | +6.0% | |
| Mar 2026 | $778.71M | +28.6% | +5.4% | |
IRONDisc Medicine, Inc. | Sep 2026 | $699.49M | +10.9% | +59.1% |
DMRADamora Therapeutics, Inc. | Mar 2026 | $535.44M | +3384.8% | +52.7% |
| Mar 2026 | $534.12M | -5.0% | +44.1% | |
| Mar 2026 | $504.61M | +186.8% | +56.4% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $467.78M | — | — |
| Mar 2026 | $312.29M | -60.2% | +3.3% | |
| Peer median (excluding DMRA) | $616.8M | +28.6% | +6.0% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 62.56M | 32.79M | 21.47M | 14.18M | 257.62M |
| Short-term Investments | 37.63M | 27.44M | 11.69M | 0 | 0 |
| Net Receivables | 2.28M | 1.38M | 1.72M | 881K | 899K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.9M | 1.5M | 1.13M | 1.19M | 1.32M |
| Total Current Assets | 110.1M | 63.91M | 36.77M | 16.84M | 260.42M |
| Property, Plant & Equipment (Net) | 1.04M | 1.17M | 325K | 130K | 104K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 9.05M | 5.83M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.03M | 2.28M | 1.13M | 163K | 0 |
| Total Non-current Assets | 12.11M | 9.28M | 1.45M | 293K | 104K |
| Total Assets | 122.22M | 73.19M | 38.23M | 17.13M | 260.53M |
| Account Payables | 1.53M | 3.35M | 1.7M | 377K | 444K |
| Short-term Debt | 399K | 476K | 183K | 12K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.01M | 6.68M | 2.96M | 604K | 1.52M |
| Total Current Liabilities | 4.54M | 11.11M | 5.83M | 1.2M | 20.07M |
| Long-term Debt | 0 | 0 | 0 | 1.36M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 43K | 28K |
| Total Non-current Liabilities | 448K | 328K | 66K | 1.46M | 81K |
| Total Liabilities | 4.99M | 11.44M | 5.9M | 2.66M | 20.15M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (156.11M) | (217.74M) | (256.08M) | (277.52M) | (487.36M) |
| Accumulated OCI | (320K) | (244K) | 380K | 97K | 802K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 117.22M | 61.75M | 32.33M | 14.47M | 240.38M |
| Total Debt | 847K | 804K | 249K | 1.43M | 68K |
| Net Debt | (61.72M) | (31.98M) | (21.22M) | (12.74M) | (257.56M) |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.